PillsCard
Reading from 50+ regulators…
Loading the latest data0%
PillsCard
Reading from 50+ regulators…
Ushbu ma'lumotlar faqat ta'lim maqsadida taqdim etilgan. U tibbiy maslahat sifatida mo'ljallanmagan. Har doim malakali tibbiyot mutaxassisiga murojaat qiling.
Tavsif, Dozalash, Nojo'ya ta'sirlar, Qarshi ko'rsatmalar. Data from EMA, URPL, openFDA and other regulatory sources.
| Salbutamol | Salmeterol | |
|---|---|---|
| Faol moddalar | Salbutamolum | Salmeterolum + Fluticasoni propionas |
| ATC kodi | R03AC02 | R03AK06 |
| Dori shakli | Aerozol inhalacyjny, zawiesina | Proszek do inhalacji, podzielony |
| Dozalash | 100 mcg/dawkę inh. | (50 mikrogramów + 250 mikrogramów)/dawkę |
| Qo'llash usuli | wziewna | wziewna |
| Ishlab chiqaruvchi | Exeltis Poland Sp. z o.o. | InPharm Sp. z o.o. |
Salbutamol (INN: Salbutamolum, ATC R03AC02) and Salmeterol (INN: Salmeterolum + Fluticasoni propionas, ATC R03AK06) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
Ushbu ma'lumotlar faqat ta'lim maqsadida taqdim etilgan. U tibbiy maslahat sifatida mo'ljallanmagan. Har doim malakali tibbiyot mutaxassisiga murojaat qiling.